Tonix Pharma Publishes Mpox Virulence Data, Advances TNX-801 Vaccine

Tonix Pharmaceuticals announced the publication of research in the Journal of Virology, detailing significant differences in mpox virus virulence between clade IIb (2022 outbreak) and clade IIa (2003 outbreak). The study, conducted at Tonix, identified three new murine models for investigating mpox pathogenesis, showing clade IIb is 100 to 100,000-fold less virulent. These findings are crucial for advancing TNX-801, Tonix's investigational live, attenuated horsepox vaccine candidate, which is expected to enter Phase 1 studies in 2027 pending FDA clearance.